9.82
前日終値:
$10.08
開ける:
$10.04
24時間の取引高:
209.04K
Relative Volume:
0.99
時価総額:
$174.17M
収益:
$1.54M
当期純損益:
$-78.54M
株価収益率:
-1.6427
EPS:
-5.978
ネットキャッシュフロー:
$-64.50M
1週間 パフォーマンス:
-4.61%
1か月 パフォーマンス:
+12.74%
6か月 パフォーマンス:
-42.64%
1年 パフォーマンス:
+30.93%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
名前
Corbus Pharmaceuticals Holdings Inc
セクター
電話
617-963-0103
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.82 | 174.17M | 1.54M | -78.54M | -64.50M | -5.978 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
775.03 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | 開始されました | Wedbush | Outperform |
| 2024-07-22 | 再開されました | H.C. Wainwright | Buy |
| 2024-06-26 | 開始されました | B. Riley Securities | Buy |
| 2024-06-03 | 繰り返されました | Oppenheimer | Outperform |
| 2024-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-08 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2020-09-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-03-26 | 開始されました | Nomura | Buy |
| 2019-04-05 | 開始されました | Jefferies | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-01-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-10-24 | 開始されました | B. Riley FBR | Buy |
| 2018-01-19 | 開始されました | Raymond James | Outperform |
| 2017-12-14 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 繰り返されました | Noble Financial | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-03-30 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-11 | 繰り返されました | Noble Financial | Buy |
すべてを表示
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN
Corbus offers upside despite post-FDA update, analyst highlights competitive edge - MSN
Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share - MSN
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Discipline and Rules-Based Execution in CRBP Response - Stock Traders Daily
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Q4 2025 earnings summary - Quartr
Corbus Pharmaceuticals (CRBP) Corporate presentation Summary - Quartr
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (CRBP) Registration Filing Summary - Quartr
Corbus Pharmaceuticals (CRBP) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 - The Manila Times
Corbus Pharmaceuticals Aligns with FDA on Cancer Drug Strategy - HarianBasis.co
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value - Insider Monkey
Corbus Pharmaceuticals updates executive employment agreements for CEO and CFO - Investing.com UK
Corbus Pharmaceuticals updates executive employment agreements for CEO and CFO By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections - TipRanks
Corbus Pharmaceuticals (NASDAQ: CRBP) resets CEO and CFO pay, severance and CIC terms - Stock Titan
Corbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists - BioWorld News
5 Best Biotech Stocks Under $10 to Buy - Insider Monkey
Corbus Pharmaceuticals (CRBP) Advances in Obesity Treatment Tria - GuruFocus
Corbus completes enrollment in obesity drug trial By Investing.com - Investing.com Australia
Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone - TipRanks
Corbus completes enrollment in obesity drug trial - Investing.com
Corbus Pharmaceuticals Holdings initiates last patient first visit in CANYON-1 obesity trial with 240 participants - Traders Union
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity - The Manila Times
Corbus Pharmaceuticals (NASDAQ: CRBP) reaches key Phase 1b obesity trial milestone for CRB-913 - Stock Titan
Corbus hits 240-patient milestone for oral obesity drug study - Stock Titan
Behavioral Patterns of CRBP and Institutional Flows - Stock Traders Daily
Published on: 2026-04-09 22:47:10 - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. secures ASCO 2026 slot for new CRB-701 clinical findings - Traders Union
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer - Sahm
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm
Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):